Generic placeholder image

Current Pharmaceutical Design

Author(s): Nikoo Saeedi, Saeide Mansoori, Fereshteh Asgharzadeh, Atena Soleimani, Samaneh Mollazadeh and Seyed Mahdi Hassanian*

DOI: 10.2174/1381612829666230524152108

DownloadDownload PDF Flyer Cite As
Influence of Renin-angiotensin System Inhibitors on the Treatment of Metastatic Renal Cancer

Page: [1459 - 1465] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are mainly known as anti-hypertensive drugs. Recent evidence suggests their anti-tumor potential against renal cancer. More than one-fourth of patients present with metastasis on their first visit.

Objective: The purpose of the current study was to examine the potential clinical impact of ACEI/ARB on metastatic renal cell carcinoma (mRCC).

Methods: We searched through several online databases, including Pubmed, Scopus, Web of Science, and Embase, to find clinical studies that have investigated the association between treatment with ACEI/ARB and the survival of patients with mRCC. The hazard ratio (HR) and 95% confidence interval (95% CI) were utilized to assess the strength of the association.

Results: A total of 6 studies with a total number of 2,364 patients were found eligible for the final analysis. The HR for the relationship between ACEI/ARB use and overall survival (OS) showed patients undergoing treatment with ACEI/ARB to have higher OS than non-users (HR: 0.664, 95% CI 0.577-0.764, p = 0.000). Furthermore, the HR for the relationship between ACEI/ARB use and progression-free survival (PFS) showed patients undergoing treatment with ACEI/ARB to have higher PFS than non-users (HR: 0.734, 95% CI 0.695-0.794, p = 0.000).

Conclusion: The results of this review offer ACEI/ARB as a potential therapeutic option associated with improved survival outcomes in patients receiving anti-vascular endothelial growth factor therapy.

[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Martel C, Lara PN. Renal cell carcinoma: Current status and future directions. Crit Rev Oncol Hematol 2003; 45(2): 177-90.
[http://dx.doi.org/10.1016/S1040-8428(02)00076-8] [PMID: 12604128]
[3]
Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373(9669): 1119-32.
[http://dx.doi.org/10.1016/S0140-6736(09)60229-4] [PMID: 19269025]
[4]
Jiang H, Tai Z, Chen Z, Zhu Q, Bao L. Clinical applicability of renin-angiotensin system inhibitors in cancer treatment. Am J Cancer Res 2021; 11(2): 318-36.
[PMID: 33575074]
[5]
Asgharzadeh F, Hashemzehi M, Moradi-Marjaneh R, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis. Life Sci 2020; 242: 117181.
[http://dx.doi.org/10.1016/j.lfs.2019.117181] [PMID: 31863771]
[6]
Sobczuk P, Szczylik C, Porta C, Czarnecka A. Renin angiotensin system deregulation as renal cancer risk factor (Review). Oncol Lett 2017; 14(5): 5059-68.
[http://dx.doi.org/10.3892/ol.2017.6826] [PMID: 29098020]
[7]
Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: The search continues. Future Med Chem 2011; 3(14): 1787-808.
[http://dx.doi.org/10.4155/fmc.11.121] [PMID: 22004085]
[8]
Shetu SA, Bandyopadhyay D. Small-molecule ras inhibitors as anticancer agents: Discovery, development, and mechanistic studies. Int J Mol Sci 2022; 23(7): 3706.
[http://dx.doi.org/10.3390/ijms23073706] [PMID: 35409064]
[9]
Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007; 22(4): 577-84.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04797.x] [PMID: 17376054]
[10]
McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21(11): 2471-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2332] [PMID: 25724518]
[11]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta- analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[12]
Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treatment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcinoma. Clin Genitourin Cancer 2017; 15(3): 384-90.e3.
[13]
Fiala O, Ostašov P, Rozsypalová A, et al. Impact of concomitant cardiovascular medication on survival of metastatic renal cell carcinoma patients treated with sunitinib or pazopanib in the first line. Target Oncol 2021; 16(5): 643-52.
[http://dx.doi.org/10.1007/s11523-021-00829-y] [PMID: 34363554]
[14]
Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ, Mangoni AA. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. Int J Cancer 2016; 138(9): 2293-9.
[http://dx.doi.org/10.1002/ijc.29972] [PMID: 26685869]
[15]
Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015; 26(6): 1128-33.
[http://dx.doi.org/10.1093/annonc/mdv147] [PMID: 25795198]
[16]
Ghidini M, Petrelli F, Ghidini A, et al. Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs 2017; 26(11): 1229-37.
[http://dx.doi.org/10.1080/13543784.2017.1384813] [PMID: 28952411]
[17]
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5): 427-34.
[http://dx.doi.org/10.1056/NEJMoa021491] [PMID: 12890841]
[18]
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803-13.
[http://dx.doi.org/10.1056/NEJMoa1510665] [PMID: 26406148]
[19]
Munro MJ, Wickremesekera AC, Davis PF, Marsh R, Tan ST, Itinteang T. Renin-angiotensin system and cancer: A review. Integr Cancer Sci Ther 2017; 4(2): 1-6.
[20]
Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17(1): 45-51.
[http://dx.doi.org/10.1016/j.gde.2006.12.007] [PMID: 17208432]
[21]
Shibayama Y, Fujimori T, Nguyen G, et al. (Pro)renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci Rep 2015; 5(1): 8854.
[http://dx.doi.org/10.1038/srep08854] [PMID: 25747895]
[22]
Solano-Iturri JD, Echevarría E, Unda M, et al. Clinical implications of (Pro)renin Receptor (PRR) expression in renal tumours. Diagnostics 2021; 11(2): 272.
[http://dx.doi.org/10.3390/diagnostics11020272] [PMID: 33578778]
[23]
Sun H, Li T, Zhuang R, Cai W, Zheng Y. Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Medicine 2017; 96(13): e6394.
[http://dx.doi.org/10.1097/MD.0000000000006394] [PMID: 28353566]
[24]
Derosa L, Izzedine H, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncol Rev 2016; 10(2): 298.
[http://dx.doi.org/10.4081/oncol.2016.298] [PMID: 27994768]
[25]
Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62(15): 4176-9.
[PMID: 12154013]
[26]
Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 2017; 9(410): eaan5616.
[http://dx.doi.org/10.1126/scitranslmed.aan5616] [PMID: 28978752]
[27]
Michel MC, Wieland T, Tsujimoto G. How reliable are G-protein- coupled receptor antibodies?. Springer 2009; pp. 385-8.
[28]
Heffelfinger S. The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 2007; 13(12): 1215-29.
[http://dx.doi.org/10.2174/138161207780618858] [PMID: 17504231]
[29]
Greco S, Muscella A, Elia MG, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 2003; 196(2): 370-7.
[http://dx.doi.org/10.1002/jcp.10313] [PMID: 12811831]
[30]
Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294(2): 441-7.
[http://dx.doi.org/10.1016/S0006-291X(02)00496-5] [PMID: 12051731]
[31]
de Araújo JRF, Leitão OALCS, de Melo SRF, de Oliveira HRA, de França CP, de Araújo AA. Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Exp Biol Med 2015; 240(1): 34-44.
[http://dx.doi.org/10.1177/1535370214546267] [PMID: 25125501]
[32]
Chen X, Meng Q, Zhao Y, et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett 2013; 328(2): 318-24.
[http://dx.doi.org/10.1016/j.canlet.2012.10.006] [PMID: 23092556]
[33]
Hii S-I, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77(6): 880-3.
[http://dx.doi.org/10.1038/bjc.1998.145] [PMID: 9528828]
[34]
Araujo W, Naves M, Ravanini JN, Teixeira V. Renin angiotensin system (RAS) blockade attenuates growth and metastasis formation of renal cell carcinoma in mice. Ann Oncol 2014; 25: iv54.
[http://dx.doi.org/10.1093/annonc/mdu325.8]
[35]
Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98(3): 671-9.
[http://dx.doi.org/10.1172/JCI118838] [PMID: 8698858]
[36]
Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013; 4(1): 2516.
[http://dx.doi.org/10.1038/ncomms3516] [PMID: 24084631]
[37]
Zhao Y, Cao J, Melamed A, et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci 2019; 116(6): 2210-9.
[http://dx.doi.org/10.1073/pnas.1818357116] [PMID: 30659155]